High-resolution 3D visualization of nanomedicine distribution in tumors

por Moss, Jennifer I., Barjat, Hervé, Emmas, Sally-Ann, Strittmatter, Nicole, Maynard, Juliana, Goodwin, Richard J. A., Storm, Gert, Lammers, Twan, Puri, Sanyogitta, Ashford, Marianne B., Barry, Simon T.
Publicado 2020

A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability

por Kuczynski, Elizabeth A, Morlino, Giulia, Peter, Alison, Coenen‐Stass, Anna M L, Moss, Jennifer I, Wali, Neha, Delpuech, Oona, Reddy, Avinash, Solanki, Anisha, Sinclair, Charles, Calado, Dinis P, Carnevalli, Larissa S
Publicado 2022

Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution

por Strittmatter, Nicole, Moss, Jennifer I., Race, Alan M., Sutton, Daniel, Canales, Jaime Rodriguez, Ling, Stephanie, Wong, Edmond, Wilson, Joanne, Smith, Aaron, Howes, Colin, Bunch, Josephine, Barry, Simon T., Goodwin, Richard J.A., Ashford, Marianne B.
Publicado 2022

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

por Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.
Publicado 2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

por Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, DeBruin, Elza, Barry, Simon T.
Publicado 2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

por Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.
Publicado 2023